Pariceract

CAT: 0804-HY-104038-01Size: 5 mgDry Ice: NoHazardous: No

1 / 1

CAT#:0804-HY-104038-01Size:5 mg

Selected

24/48H Stock Items & 2 to 6 Weeks non Stock Items.

Quick Request Actions

Description

Pariceract (LTI-291) is an activator of glucocerebrosidase (Gcase), with activation rates of more than 60% (1 μM) and between 10%-20% (0.1 μM) . Pariceract can be used for Parkinson's disease and endometriosis research[1].

CAS Number

1919820-28-2

Product Name Alternative

LTI-291; BIA 28-6156

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Glycosidase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Endocrinology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/LTI-291.html

Concentration

10mM

Purity

99.11

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(C1=C2N=C(C)C=C(C)N2N=C1)N[C@@H]3CC[C@@H](OCCCCC)CC3

Molecular Formula

C20H30N4O2

Molecular Weight

358.48

Precautions

H302, H315, H319, H335

References & Citations

[1]Renato T. Skerlj, et al. Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds. WO 2017192841 A1.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Pariceract

Popular Products